Original Article

You have full text access to this OnlineOpen article

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

  1. Joseph M. Unger M.S.1,†,*,
  2. Ian M. Thompson Jr. M.D.2,
  3. Michael LeBlanc Ph.D.1,
  4. John J. Crowley Ph.D.1,
  5. Phyllis J. Goodman M.S.1,
  6. Leslie G. Ford M.D.3,
  7. Charles A. Coltman Jr. M.D.4

Article first published online: 28 FEB 2005

DOI: 10.1002/cncr.20919

Issue

Cancer

Cancer

Volume 103, Issue 7, pages 1375–1380, 1 April 2005

Additional Information

How to Cite

Unger, J. M., Thompson, I. M., LeBlanc, M., Crowley, J. J., Goodman, P. J., Ford, L. G. and Coltman, C. A. (2005), Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer, 103: 1375–1380. doi: 10.1002/cncr.20919

Author Information

  1. 1

    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington

  2. 2

    University of Texas Health Science Center, San Antonio, San Antonio, Texas

  3. 3

    National Cancer Institute, Bethesda, Maryland

  4. 4

    Southwest Oncology Group Operations Office, San Antonio, Texas

  1. †

    Fax: (210) 677-0006

*Southwest Oncology Group (SWOG-9217), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217

Publication History

  1. Issue published online: 18 MAR 2005
  2. Article first published online: 28 FEB 2005
  3. Manuscript Accepted: 3 DEC 2004
  4. Manuscript Revised: 22 NOV 2004
  5. Manuscript Received: 5 AUG 2004

Funded by

  • National Cancer Institute, Department of Health and Human Services. Grant Numbers: CA37429, CA38926, CA32102

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (151K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nikki A. Ford, Nancy Engelmann Moran, Joshua W. Smith, Steven K. Clinton, John W. Erdman, An interaction between carotene-15,15′-monooxygenase expression and consumption of a tomato or lycopene-containing diet impacts serum and testicular testosterone, International Journal of Cancer, 2012, 131, 2
    Direct Link:
  2. 2
    Charles Carter, James Stallworth, Robert Holleman, Textbook of Family Medicine, 2012,

    CrossRef

  3. 3
    Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta, Chemoprevention of prostate cancer: is there evidence from clinical trials?, Clinical Investigation, 2011, 1, 9, 1257

    CrossRef

  4. 4
    E. David Crawford, Gerald L. Andriole, Michael Marberger, Roger S. Rittmaster, Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial, Urology, 2010, 75, 3, 502

    CrossRef

  5. 5
    David F. Penson, Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis, Urologic Oncology: Seminars and Original Investigations, 2008, 26, 5, 564

    CrossRef

  6. 6
    Robert S. Svatek, J. Jack Lee, Claus G. Roehrborn, Scott M. Lippman, Yair Lotan, Cost-effectiveness of prostate cancer chemoprevention, Cancer, 2008, 112, 5
    Direct Link:
  7. 7
    Jamey A. Sarvis, Ian M. Thompson, Prostate cancer chemoprevention: Update of the prostate cancer prevention trial findings and implications for clinical practice, Current Oncology Reports, 2008, 10, 6, 529

    CrossRef

  8. 8
    Hendrik van Poppel, Sten Nilsson, Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?, Urology, 2008, 71, 6, 1001

    CrossRef

  9. 9
    Ian M. Thompson, M. Scott Lucia, Mary W. Redman, Amy Darke, Francisco G. La Rosa, Howard L. Parnes, Scott M. Lippman, Charles A. Coltman, Finasteride Decreases the Risk of Prostatic Intraepithelial Neoplasia, The Journal of Urology, 2007, 178, 1, 107

    CrossRef

  10. 10
    Alberto Briganti, Felix K.-H. Chun, Nazareno Suardi, Andrea Gallina, Jochen Walz, Markus Graefen, Shahrokh Shariat, Andreas Ebersdobler, Patrizio Rigatti, Paul Perrotte, Fred Saad, Francesco Montorsi, Hartwig Huland, Pierre I. Karakiewicz, Prostate volume and adverse prostate cancer features: Fact not artifact, European Journal of Cancer, 2007, 43, 18, 2669

    CrossRef

  11. 11
    Gerald Andriole, 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond, European Urology Supplements, 2006, 5, 12, 746

    CrossRef

  12. 12
    Tim Byers, Ermilo Barrera, Elizabeth T. H. Fontham, Lisa A. Newman, Carolyn D. Runowicz, Stephen F. Sener, Michael J. Thun, Sara Winborn, Richard C. Wender, A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015, Cancer, 2006, 107, 2
    Direct Link:
  13. 13
    Andrea Tubaro, Cosimo de Nunzio, Against the motion, European Urology, 2006, 49, 2, 398

    CrossRef

  14. 14
    Mischel G. Neill, Neil E. Fleshner, An update on chemoprevention strategies in prostate cancer for 2006, Current Opinion in Urology, 2006, 16, 3, 132

    CrossRef

  15. 15
    G.L. Andriole, Do the Benefits of Finasteride Outweigh the Risks in the Prostate Cancer Prevention Trial?, Yearbook of Urology, 2006, 2006, 185

    CrossRef

  16. 16
    Michael Marberger, Drug Insight: 5α-reductase inhibitors for the treatment of benign prostatic hyperplasia, Nature Clinical Practice Urology, 2006, 3, 9, 495

    CrossRef

  17. 17
    Ian M. Thompson, Eric A. Klein, Catherine M. Tangen, Scott Lippman, Editorial comment, The Journal of Urology, 2006, 175, 3, 938

    CrossRef

  18. 18
    Mikel Gray, Terran Sims, Prostate Cancer, The Nurse Practitioner, 2006, 31, 9, 14???29

    CrossRef

  19. 19
    Pierre Teillac, Per-Anders Abrahamsson, The Prostate Cancer Prevention Trial and Its Implications for Clinical Practice: A European Consensus, European Urology Supplements, 2006, 5, 9, 640

    CrossRef

  20. 20
    Joseph M. Unger, Michael LeBlanc, Ian M. Thompson, Charles A. Coltman, Author reply, Cancer, 2005, 104, 7
    Direct Link:
  21. 21
    Chemoprevention of prostate cancer: a new analysis, Nature Clinical Practice Urology, 2005, 2, 4, 159

    CrossRef

  22. 22
    Mark A. Rubin, Yves Allory, Vincent Molinié, Xavier Leroy, Hugo Faucon, Francis Vacherot, Wei Huang, Adam Kuten, Laurent Salomon, Xavier Rebillard, Olivier Cussenot, Claude Abbou, Alexandre de la Taille, Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome, Urology, 2005, 66, 5, 930

    CrossRef

  23. 23
    Steven B. Zeliadt, Ruth Etzioni, Alan R. Kristal, Estimated impact of the prostate cancer prevention trial on population mortality, Cancer, 2005, 104, 7
    Direct Link:
  24. 24
    Ian M. Thompson, Carlos Bermejo, Javier Hernandez, Joseph A. Basler, Edith Canby-Hagino, Screening for Prostate Cancer: Opportunities and Challenges, Surgical Oncology Clinics of North America, 2005, 14, 4, 747

    CrossRef

  25. 25
    J. Kilian Mellon, The finasteride prostate cancer prevention trial (PCPT) – What have we learned?, European Journal of Cancer, 2005, 41, 13, 2016

    CrossRef

  26. 26
    Shin Egawa, Will the Prostate Cancer Prevention Trial affect population mortality rates?, Nature Clinical Practice Urology, 2005, 2, 11, 526

    CrossRef

View Full Article (HTML) Get PDF (151K)